

Petition For *Inter Partes* Review  
Patent No. 8,476,010

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE PATENT TRIAL AND APPEAL BOARD

J KYLE BASS and ERICH SPANGENBERG

Petitioner

v.

FRESENIUS KABI USA, LLC

Patent Owner

U.S. Patent No. 8,476,010 B2

Mailed: November 25, 2015

**PETITION FOR *INTER PARTES* REVIEW OF  
U.S. PATENT NO. 8,476,010  
AND MANDATORY NOTICES UNDER 37 C.F.R. § 42.8**

**TABLE OF CONTENTS**

I.	INTRODUCTION.....	1
II.	SUMMARY OF ARGUMENT .....	1
III.	MANDATORY NOTICES UNDER 37 C.F.R. § 42.8(a)(1).....	2
	A. Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1) .....	2
	B. Related Matters Under 37 C.F.R. § 42.8(b)(2).....	3
	C. Lead And Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3).....	4
	D. Service Information Under 37 C.F.R. § 42.8(b)(4) .....	4
IV.	PAYMENT OF FEE UNDER 37 C.F.R. § 42.103.....	4
V.	REQUIREMENTS FOR <i>INTER PARTES</i> REVIEW UNDER 37 C.F.R. § 42.104 .....	4
	A. Grounds For Standing Under 37 C.F.R. § 42.104(a).....	4
	B. Identification of Challenge Under 37 C.F.R. § 42.104(b) And Statement of Precise Relief Requested .....	5
VI.	THRESHOLD REQUIRMENT FOR INTER PARTES REVIEW .....	6
VII.	THE LEVEL OF ORDINARIRY SKILL IN THE ART .....	7
VIII.	HOW THE CHALLENGED CLAIMS ARE TO BE CONSTRUED .....	8
IX.	STEMENT OF REASONS FOR RELIEF REQUESTED .....	12
X.	BACKGROUND AND STATE OF THE ART .....	13
XI.	SUMMARY OF ‘010 PATENT .....	18
XII.	GROUND 1: CLAIMS 1, 13-15,17, 18, 20, AND 24-28 ARE OBVIOUS OVER THE PRIOR ART OF THE DIPRIVAN PDR, FARINOTTI, AND THE ‘864 PATENT .....	22

Petition For *Inter Partes* Review

Patent No. 8,476,010

XIII. GROUND 2: CLAIMS 1, 13-15,17, 18, 20, AND 24-28 ARE OBVIOUS OVER THE PRIOR ART OF THE DIPRIVAN PDR, FARINOTTI, AND THE WO'043 PATENT..... 34

XIV. SECONDARY CONSIDERATIONS, EVEN IF CONSIDERED, FAIL TO OVERCOME THE EVIDENCE OF OBVIOUSNESS..... 38

XV. CONCLUSION ..... 39

## CASES CITED

<i>Alcon Research, Ltd. v. Apotex Inc.</i> , 687 F.3d 1362 (Fed. Cir. 2012), <i>cert denied</i> , 133 S. Ct. 1736 (2013).....	23, 26
<i>Daiichi Sankyo Co. v. Apotex Inc.</i> , 501 F.3d 1254 (Fed. Cir. 2007) .....	8
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	22, 33
<i>Leapfrog Enters. Inc. v. Fisher-Price Inc.</i> , 485 F.3d 1157 (Fed. Cir. 2007) .....	39
<i>Par Pharm. Inc. v. TWI Pharms., Inc.</i> , 773 F.3d 1186, No. 2014-1391, 2014 U.S. App. LEXIS 22737 (Fed. Cir. Dec. 3, 2014) .....	22
<i>Richardson-Vicks, Inc. v. Upjohn Co.</i> , 122 F.3d 1476 (Fed. Cir. 1997) .....	39
<i>Zeneca, Inc. v. Shalala</i> , 213 F.3d 161 (4th Cir. 2000).....	17

## STATUTES, RULES & OTHER AUTHORITIES

35 U.S.C. § 102(b) .....	<i>passim</i>
35 U.S.C. § 103(a) .....	3, 17
35 U.S.C. § 314(a).....	4
37 C.F.R. § 42.100(b).....	13

**EXHIBIT LIST**

<b>Exhibit</b>	<b>Reference</b>
1001	U.S. Patent No. 8,476,010
1002	Declaration of Thomas N. Feinberg, Ph.D
1003	<i>Curriculum Vitae</i> of Thomas N. Feinberg, Ph.D
1004	Smith <i>et al.</i> , "Siliconization of Parenteral Drug Packaging Components," 1988, 42 <i>J. of Parenteral Sci. and Tech.</i> (1988 Supp.)
1005	Entry for Diprivan® in the Physician's Desk Reference, 51st Edition, 1997, pp. 341, 2939-2945
1006	R. Farinotti, "Physio-chemical Interactions and Storage of Diprivan®," <i>Ann. Fr. Anesth. Reanim.</i> , 1994 (French
1007	Certified English-Language Translation of Exhibit 1006
1008	August 3, 2001 Web page for Diprivan® FAQs
1009	Han <i>et al.</i> , "Physical properties and stability of two emulsion formulations of propofol," <i>Int'l J. of Pharmaceutics</i> , 215 (2001) 207-220
1010	U.S. Patent No. 5,383,864
1011	West Technical Support Bulletin 1999/013, "Evaluating B2-Coating as an Alternative to Silicone Oil," January 26, 1999
1012	West Technical Report 2000/026, "B2-Coating Quantitative Particle Analysis," November 15, 2000
1013	"Siliconization: As Applied to Containers and Closures," <i>Bulletin of the Parenteral Drug Association</i> , Vol. 22, No. 2 March/April
1014	U.S. Patent No. 5,714,520
1015	Complaint from Civil Action No. 14-cv-00160-RGA (D. Del.), Dkt. 1 (filed February 6, 2014)
1016	Waiver of Service of Summons from Civil Action No. 14-cv-00160-RGA (D. Del.), Dkt. 5 (filed March 10, 2014)
1017	September 6, 2007 Response to Office Action, U.S. Serial No. 10/616,709
1018	July 13, 2012 Office Action, U.S. Serial No. 10/616,709
1019	December 16, 2010 Response to Office Action, U.S. Serial No. 10/616,709

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.